Peanut Health Completes New Funding Round and Upgrades to an AI-Driven, Full-Lifecycle Digital Health Platform for Men's and Women's Wellness

Recently, in the field of women's health across the entire life cyclePeanut HealthAnnounced the completion of a new round of financing, led byPuhuaPuhua Capital, Xiaochi Fund, Jiaxing XinyiJoint Investment.

Peanut Health, founded in 2014, has established nearly 30 medical institutions across 15 cities, accumulating over 100,000 verified physician profiles and more than 3 million structured medical record entries. As the largest reproductive health vertical platform in China, its subsidiary “Haoyunbang” has gathered data from 12 million users. Since 2019, Peanut Medical has deployed its self-developed “Peanut Cloud” system, laying a solid foundation for Peanut Health’s transformation into an AI-driven digital health management platform. Currently, Peanut Health has achieved deep AI integration across multiple areas, including patient education, health consultations, medical record generation, case management, and member operations.

Since achieving significant revenue in 2019, the company has doubled its income for six consecutive years. Revenue is projected to exceed RMB 1 billion in 2026, with non-medical-insurance-covered revenue accounting for over 99%.Peanut Health adheres to the growth strategy of “refining specialized disease solutions within specific medical specialties and building expert physician IPs through specialized disease content.” Using reproductive medicine as a trust anchor, it extends into high-margin, high-repeat-purchase scenarios such as weight management, medical aesthetics, and anti-aging, thereby covering both male and female users.

In the expansion of specialized disease areas, centering on the sex hormone axis, we focus on four core value propositions:Appearance(Weight/Skin/Hair),Performance(Sexual Health/Vitality),Reproduction(Preconception Care/Fetal Preservation)Anti-aging(Function/Regeneration), select design solutions for complex specialized diseases that require the integration of MDT and governance.

We are in an era of accelerated innovation in healthcare and wellness, with new drugs, devices, and therapies continually emerging. The traditional industry chain—centered on the core mission of “ensuring basic coverage”—including processes such as price setting, inclusion in reimbursement catalogs, waiting for tender bids, negotiating terms, departmental requisitions, and hospital formulary listings, may no longer fully meet the demand for efficiency in accessing innovative outcomes among healthcare consumers. Direct-to-consumer (DTC) health management platforms can serve as a valuable complement to the basic healthcare system.

Upon the completion of this funding round, the company’s brand has been comprehensively upgraded to “Peanut Health.” Adhering to its corporate values of “Professionalism, Empathy, and Integrity,” the company is fully benchmarking against “Hims & Hers.” It leverages sexual health as an entry point, utilizes multi-disease expansion as a growth flywheel, integrates high-quality medical resources through IP-driven content, and shapes user perception via new media marketing. The company continues to invest in the comprehensive implementation of AI in healthcare, refining a closed-loop system characterized by “online-offline mutual conversion and multi-point delivery of products and services,” with the aim of building an AI-driven digital health management platform.

Expansion of specialized disease categories for both sexes and R&D of organoids in the reproductive field have been strengthened. The company has undergone three developmental stages: “Haoyunbang,” “Huasheng Medical,” and “Huasheng Health,” evolving from a focus on “reproductive health” to “women’s health across the entire life cycle,” and finally to an “AI-driven management platform for specialized diseases affecting both sexes.” Adopting a lean startup approach, the team has rapidly iterated its offerings to capture the certainties of value-based healthcare in a dynamic market. The project has secured multiple rounds of financing from prominent investment institutions, including Gene Capital, Puhua Capital, Chongshan Capital, Boxing Capital, and Zero2IPO Industrial Investment. In 2025, the company initiated preparations for its initial public offering (IPO) on the Hong Kong Stock Exchange.

Yin Jie, Founding Partner of Xiaochi FundIt stated that Peanut Health has accumulated a substantial user base through ten years of industry immersion. By centering on health across the entire life cycle for both men and women, it has extended its business from serious medical care to consumer health. Leveraging its large-scale user community and offline clinics, the company has established a true data closed loop, effectively unlocking the implementation potential of AI in healthcare and significantly improving the efficiency and personalization of medical services. We believe that Peanut Health is at a critical stage of transitioning from a chain medical group to a data-driven, intelligent health platform. The depth of its user retention, the extent of its service expansion, and the potential of AI empowerment are the core factors underlying our optimism about its long-term development.